Search

Displaying results 771 - 780 of 4265 in total
  1. Drug

    Mebendazole

    go.drugbank.com/drugs/DB00643
    ApprovedInvestigationalVet approved

    A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

  2. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.

  3. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated

  4. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]

  5. Drug

    Topotecan

    go.drugbank.com/drugs/DB01030
    ApprovedInvestigational

    It works by inhibiting DNA topoisomerases, type I.

  6. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

  7. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and ...

  8. Drug

    Aztreonam

    go.drugbank.com/drugs/DB00355
    ApprovedInvestigational

    A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinf...

  9. Drug

    Modafinil

    go.drugbank.com/drugs/DB00745
    ApprovedInvestigational

    Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. … The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular

  10. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940] … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.